Healthcare -
Drug Manufacturers - General - NYSE - US
$ 188.37
-4.55 %
$ 333 B
Market Cap
79.98
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
AbbVie Inc.
| Net Income | 4.29 B |
| Depreciation & Amortization | 8.39 B |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 911 M |
| Change in Working Capital | 0 |
| Others | 6.67 B |
| Free Cash Flow | 17.8 B |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||||||
| Net Income | 4 286.0 | 4 873.0 | 11 845.0 | 11 549.0 | 4 622.0 | 7 882.0 | 5 687.0 | 5 309.0 | 5 953.0 | 5 144.0 | 1 774.0 | 4 128.0 | 5 275.0 | 3 433.1 | 4 178.0 | 4 636.5 |
| Depreciation & Amortization | 8 386.0 | 8 698.0 | 8 467.0 | 8 521.0 | 6 471.0 | 2 017.0 | 1 765.0 | 1 501.0 | 1 189.0 | 836.0 | 786.0 | 897.0 | 1 150.0 | 1 272.2 | 1 184.0 | 697.5 |
| Deferred Income Tax | (1 449.0) | (2 889.0) | (1 931.0) | (898.0) | (2 325.0) | 700.0 | 424.0 | 1 242.0 | 298.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 911.0 | 747.0 | 671.0 | 692.0 | 753.0 | 430.0 | 421.0 | 365.0 | 353.0 | 282.0 | 241.0 | 212.0 | 187.0 | 163.0 | 167.0 | 156.7 |
| Other Operating Activities | 6 672.0 | 8 597.0 | 6 149.0 | 4 235.0 | 7 961.0 | 3 624.0 | 6 256.0 | 1 534.0 | 937.0 | 769.0 | 1 536.0 | 372.0 | 354.0 | 672.5 | 313.0 | (627.1) |
| Change in Working Capital | 0 | 2 813.0 | (258.0) | (1 322.0) | 106.0 | (1 329.0) | (1 126.0) | 9.0 | (1 689.0) | 504.0 | (788.0) | 658.0 | (621.0) | 706.2 | (866.0) | 503.7 |
| Cash From Operations | 18 806.0 | 22 839.0 | 24 943.0 | 22 777.0 | 17 588.0 | 13 324.0 | 13 427.0 | 9 960.0 | 7 041.0 | 7 535.0 | 3 549.0 | 6 267.0 | 6 345.0 | 6 247.0 | 4 976.0 | 5 367.3 |
| INVESTING CASH FLOW | ||||||||||||||||
| Capital Expenditures | 0 | (777.0) | (695.0) | (787.0) | (798.0) | (552.0) | (638.0) | (529.0) | (479.0) | (532.0) | (612.0) | (491.0) | (333.0) | (355.5) | (448.0) | (312.6) |
| Other Items | (20 820.0) | (1 232.0) | 72.0 | (1 557.0) | (36 759.0) | 1 148.0 | (368.0) | 255.0 | (5 595.0) | (12 404.0) | (314.0) | 1 370.0 | (2 085.0) | 909.4 | (4 583.0) | (173.8) |
| Cash From Investing Activities | (20 820.0) | (2 009.0) | (623.0) | (2 344.0) | (37 557.0) | 596.0 | (1 006.0) | (274.0) | (6 074.0) | (12 936.0) | (926.0) | 879.0 | (2 418.0) | 553.9 | (5 031.0) | (486.4) |
| FINANCING CASH FLOW | ||||||||||||||||
| Common Stock Repurchased | (1 708.0) | (1 972.0) | (1 487.0) | (934.0) | (978.0) | (629.0) | (12 014.0) | (1 410.0) | (6 033.0) | (7 586.0) | (665.0) | (320.0) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 7 350.0 | (4 149.0) | (12 433.0) | (8 414.0) | (2 683.0) | 26 247.0 | 3 229.0 | (25.0) | 5 594.0 | 16 623.0 | (5.0) | (601.0) | 15 586.0 | (21.1) | 0 | (34.8) |
| Dividends Paid | (11 025.0) | (10 539.0) | (10 043.0) | (9 261.0) | (7 716.0) | (6 366.0) | (5 580.0) | (4 107.0) | (3 717.0) | (3 294.0) | (2 661.0) | (2 555.0) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 172.0 | (562.0) | (840.0) | (430.0) | (124.0) | (544.0) | (31.0) | 30.0 | 228.0 | 9.0 | 38.0 | 34.0 | (13 655.0) | (6 761.9) | 65.0 | (4 846.4) |
| Cash From Financing Activities | (5 211.0) | (17 222.0) | (24 803.0) | (19 039.0) | (11 501.0) | 18 708.0 | (14 396.0) | (5 512.0) | (3 928.0) | 5 752.0 | (3 293.0) | (3 442.0) | 1 931.0 | (6 783.0) | 65.0 | (4 881.2) |
| CHANGE IN CASH | ||||||||||||||||
| Net Change In Cash | (7 290.0) | 3 613.0 | (545.0) | 1 297.0 | (31 475.0) | 32 635.0 | (2 014.0) | 4 203.0 | (3 299.0) | 51.0 | (1 247.0) | 3 694.0 | 5 874.0 | 17.8 | 65.0 | (0.2) |
| FREE CASH FLOW | ||||||||||||||||
| Free Cash Flow | 17 832.0 | 22 062.0 | 24 248.0 | 21 990.0 | 16 790.0 | 12 772.0 | 12 789.0 | 9 431.0 | 6 562.0 | 7 003.0 | 2 937.0 | 5 776.0 | 6 012.0 | 5 891.4 | 4 528.0 | 5 054.8 |